Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Versant Ventures
Deal Size : $94.0 million
Deal Type : Series A Financing
Firefly Bio Debuts with $94 Million Series A Financing
Details : The financing aims to support Firefly developing a platform for cancer treatment utilizing degrader antibody conjugates. It represents the integration of two technologies: ADCs and protein degraders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 15, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Versant Ventures
Deal Size : $94.0 million
Deal Type : Series A Financing